Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Avalon GloboCare Corp Market Cap
The Avalon GloboCare Corp (AVCO) share price is expected to decrease by 100% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered AVCO. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for AVCO is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
Avalon GloboCare Corp has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Avalon GloboCare Corp will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of AVCO.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
When did it IPO
2016
Staff Count
0
Country
United States
Sector/Industry
/
CEO
Market Cap
$21.2M
In 2023, AVCO generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AVCO's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 08 Nov 2022
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The company is acquiring a majority stake in Laboratory Services MSO, LLC, which had over $25 million in revenue and $10 million in net income in 2021, completing over 600,000 tests.
Why It Matters - The acquisition signals growth potential and diversification for the company, likely enhancing revenue and profitability, which could positively impact stock performance and investor sentiment.
Wed, 09 Nov 2022
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The company will start trading under the new ticker symbol "ALBT" on November 10, 2022.
Why It Matters - A new trading symbol can impact visibility and investor perception, potentially influencing trading volumes and stock performance for the company.
Thu, 29 Sep 2022
Sentiment - NEUTRAL
Source - Proactive Investors
Summary - Avalon GloboCare Corp (NASDAQ:AVCO) received a patent allowance for its QTY fusion water-soluble receptor protein platform, potentially enhancing drug development and clinical applications.
Why It Matters - Avalon GloboCare's patent allowance enhances its technological edge, potentially increasing its market value and attracting investment through expanded clinical applications and drug development opportunities.
Thu, 29 Sep 2022
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The Company, in collaboration with MIT, has submitted a new U.S. patent application for QTY glucose transporters.
Why It Matters - The patent application indicates potential for innovation in glucose transport technology, which could enhance the company's market position and drive future revenue growth.
Thu, 29 Sep 2022
Sentiment - POSITIVE
Source - PennyStocks
Summary - The stock market experienced notable movements today. Additionally, three penny stocks have been highlighted for potential investment this week.
Why It Matters - Market updates and penny stock insights can indicate potential investment opportunities or risks, influencing trading strategies and portfolio adjustments.
Mon, 08 Aug 2022
Sentiment - POSITIVE
Source - Proactive Investors
Summary - Avalon GloboCare Corp (NASDAQ:AVCO) announced that its QTY protein code technology was featured in Chemical Reviews, highlighting its potential for generating water-soluble proteins for biomedical uses.
Why It Matters - Avalon GloboCare's recognition in a prestigious journal highlights its innovative technology, potentially boosting credibility and attracting investment interest in its biomedical applications.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
